These authors contributed equally to this study.
Steatohepatitis/Metabolic Liver Disease
Mitochondria-targeted ubiquinone (MitoQ) decreases ethanol-dependent micro and macro hepatosteatosis†
Article first published online: 24 JUN 2011
Copyright © 2011 American Association for the Study of Liver Diseases
Volume 54, Issue 1, pages 153–163, July 2011
How to Cite
Chacko, B. K., Srivastava, A., Johnson, M. S., Benavides, G. A., Chang, M. J., Ye, Y., Jhala, N., Murphy, M. P., Kalyanaraman, B. and Darley-Usmar, V. M. (2011), Mitochondria-targeted ubiquinone (MitoQ) decreases ethanol-dependent micro and macro hepatosteatosis. Hepatology, 54: 153–163. doi: 10.1002/hep.24377
Funding: This study was supported by the National Institutes of Health [grant number AA013395] to V.D.U. Dr. Michael P. Murphy holds patents related to the area of mitochondria-targeted antioxidants as therapies and serves on the scientific advisory board of Antipodean Pharmaceuticals Inc. that develops and commercializes MitoQ.
- Issue published online: 24 JUN 2011
- Article first published online: 24 JUN 2011
- Accepted manuscript online: 21 APR 2011 07:49AM EST
- Manuscript Accepted: 8 APR 2011
- Manuscript Received: 16 NOV 2010
Additional Supporting Information may be found in the online version of this article.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.